Suraksha Diagnostic Ltd is Rated Sell

Current Rating and Its Significance

MarketsMOJO’s 'Sell' rating for Suraksha Diagnostic Ltd indicates a cautious stance for investors considering this stock. This recommendation is based on a comprehensive evaluation of four key parameters: Quality, Valuation, Financial Trend, and Technicals. The rating suggests that, given the present data, the stock may underperform relative to the broader market or its sector peers, and investors should carefully assess the risks before committing capital.

Rating Update Context

The rating was revised to 'Sell' on 01 June 2026, reflecting a significant change in the company’s outlook. At that time, the Mojo Score dropped by 21 points, from 57 (Hold) to 36 (Sell), signalling a marked deterioration in the stock’s overall assessment. It is important to note that while the rating change occurred in early June, all financial data and performance metrics referenced here are current as of 29 July 2026, ensuring that investors receive the most recent and relevant information.

Quality Assessment

Suraksha Diagnostic Ltd’s quality grade remains classified as 'good', indicating that the company maintains a reasonable standard in operational efficiency and business fundamentals. Despite this, recent quarterly results have raised concerns. The operating profit to interest ratio for the quarter ending March 2026 stood at a low 6.22 times, signalling tighter coverage of interest expenses. Additionally, the profit after tax (PAT) for the same quarter was ₹6.28 crores, reflecting a decline of 24.6% compared to the previous four-quarter average. These figures suggest that while the company’s core business remains intact, profitability pressures are mounting.

Valuation Perspective

From a valuation standpoint, the stock is currently rated as 'attractive'. This implies that, based on price multiples and relative market comparisons, Suraksha Diagnostic Ltd may be trading at a discount or reasonable levels relative to its intrinsic value. However, valuation attractiveness alone does not offset the risks posed by deteriorating financial trends and technical weakness. Investors should weigh this factor carefully against other metrics before making investment decisions.

Financial Trend Analysis

The financial trend for Suraksha Diagnostic Ltd is categorised as 'negative'. The company’s debt-equity ratio as of the half-year period is at a relatively high 0.53 times, indicating increased leverage. This elevated debt level, combined with declining profitability, raises concerns about the company’s ability to sustain growth and manage financial obligations effectively. Furthermore, the stock has delivered negative returns over multiple time frames, including a 1-year return of -18.32% and a 6-month return of -3.44%, underscoring the challenging financial environment the company currently faces.

Technical Outlook

Technically, the stock is rated as 'bearish'. Recent price movements show a downward trend, with the stock declining 8.94% over the past month and 11.38% over the last three months. The one-week performance also reflects weakness, with a 3.87% drop. Although there was a modest gain of 0.34% on the day of analysis (29 July 2026), the overall technical indicators suggest limited near-term upside potential. This bearish technical stance aligns with the broader negative financial trend and supports the current 'Sell' rating.

Comparative Performance and Market Context

Suraksha Diagnostic Ltd’s performance has lagged behind key benchmarks such as the BSE500 index over the last one year, three years, and three months. The stock’s underperformance relative to the broader market highlights the challenges it faces within the healthcare services sector. Investors should consider this relative weakness when evaluating the stock’s potential for recovery or growth.

Implications for Investors

For investors, the 'Sell' rating serves as a cautionary signal. It suggests that the stock currently exhibits a combination of financial stress, technical weakness, and limited growth prospects despite an attractive valuation. Investors holding Suraksha Diagnostic Ltd shares may want to reassess their positions in light of these factors, while prospective buyers should approach with prudence and conduct thorough due diligence.

Summary of Key Metrics as of 29 July 2026

To summarise, the stock’s key performance indicators as of today are as follows:

• Mojo Score: 36.0 (Sell grade)
• Market Capitalisation: Microcap segment
• Debt-Equity Ratio (Half Year): 0.53 times
• Operating Profit to Interest Coverage (Quarterly): 6.22 times
• Profit After Tax (Quarterly): ₹6.28 crores, down 24.6%
• Stock Returns: 1 Day +0.34%, 1 Week -3.87%, 1 Month -8.94%, 3 Months -11.38%, 6 Months -3.44%, Year-to-Date -6.80%, 1 Year -18.32%

These figures collectively illustrate the challenges Suraksha Diagnostic Ltd is currently facing, reinforcing the rationale behind the 'Sell' rating.

Looking Ahead

Investors should monitor upcoming quarterly results and any strategic initiatives the company undertakes to improve its financial health and market position. Improvements in profitability, debt management, and technical momentum could warrant a reassessment of the rating in the future. Until then, the current data advises caution.

Conclusion

Suraksha Diagnostic Ltd’s 'Sell' rating by MarketsMOJO, last updated on 01 June 2026, reflects a comprehensive evaluation of the company’s current financial and market standing as of 29 July 2026. While the stock’s valuation appears attractive, negative financial trends and bearish technical indicators suggest limited upside potential. Investors should carefully consider these factors in their portfolio decisions and remain vigilant for any changes in the company’s outlook.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →